RenalSense
Jerusalem
About RenalSense
While prevention of kidney injury is highly dependent on early detection of potential risk, the industry has no solutions to address this need. Conventional products and protocols can only report kidney damage after it exists - not prevent it. The growing unmet need for early detection and prevention of risk and for the tools to improve the management of AKI patients in critical care have established the necessity of realtime renal diagnostics solutions. RenalSense's unique products will set new clinical gold standards, improve outcomes and reduce the cost of care.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $14.8M
- Funding stage: Early Stage Venture
- Last round: Series A (Nov 2021)
- Website: renalsense.com
- Phone: (617) 274-5753
Industries & Categories
Biotechnology, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/renalsense-71461 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.